ArticleScientific reports2025

Cost-effectiveness analysis of nimotuzumab combined with gemcitabine for K-Ras wild type locally advanced or metastatic pancreatic cancer in China.

Rong Long et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.